文献速递肾癌与肾肿瘤

PADRES:新辅助阿昔替尼用于复杂部分肾切除术的2期临床试验

PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy.
PubMed 文献 · BJU Int · 2024-01-11

PADRES是一项单臂2期临床试验,纳入27例RENAL评分10-12分、需保留肾单位但部分肾切除术高风险的局限性透明细胞肾细胞癌患者,术前接受阿昔替尼5 mg每日两次共8周。肿瘤直径和RENAL评分显著下降,74.0%患者完成计划的部分肾切除术,96.2%切缘阴性,22.2%发生Clavien III-IV级并发症。

要点

  • 阿昔替尼5 mg每日两次共8周使肿瘤直径从7.5 cm降至6.2 cm、RENAL评分从11降至10(均P<0.001)。
  • 27例中20例(74.0%)完成部分肾切除术,25例(96.2%)切缘阴性。
  • 6例(22.2%)发生Clavien III-IV级并发症,中位eGFR变化为8.5 mL/min/1.73 m2。

核心结论

  • 新辅助阿昔替尼使复杂肾 masses 且具有保留肾单位绝对指征患者的肿瘤体积和复杂性降低,使部分肾切除术安全可行并保留肾功能。

研究设计与样本

  • 单臂2期临床试验(PADRES,NCT03438708),纳入27例局限性(cT1b-cT3M0)透明细胞肾细胞癌且因复杂性(RENAL评分10-12)部分肾切除术高风险、有保留肾单位绝对指征的患者。
  • 阿昔替尼5 mg每日两次给药8周,完成时重复影像学检查,随后手术。
  • 主要结局为阿昔替尼治疗后成功完成计划的部分肾切除术;次要目标包括肿瘤直径、RENAL评分、肾功能、RECIST v1.1和手术并发症的变化。

主要发现

  • 27例患者入组,中位年龄69岁;治疗前20例(74.0%)为≥临床T3a期肿瘤。
  • 阿昔替尼使肿瘤直径降低(7.5 vs 6.2 cm;P < 0.001),RENAL评分降低(11 vs 10;P < 0.001)。
  • 9例(33.3%)基于RECIST达到部分缓解,9例(33.3%)临床降期。
  • 20例(74.0%)接受了部分肾切除术;25例(96.2%)切缘阴性;6例(22.2%)发生Clavien III-IV级并发症。
  • 估计肾小球滤过率(术前至末次随访)的中位变化为8.5 mL/min/1.73 m2。

临床怎么用

  • 原文结论认为新辅助阿昔替尼使复杂肾 masses 且具有保留肾单位绝对指征患者的肿瘤体积和复杂性降低,使部分肾切除术安全可行并保留肾功能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the results of PADRES (Prior Axitinib as a Determinant of Outcome of Renal Surgery, NCT03438708), a study investigating neoadjuvant axitinib for tumours of high complexity with imperative indication for partial nephrectomy (PN). METHODS: We conducted a single-arm phase II clinical trial of localized (cT1b-cT3M0) clear-cell renal cell carcinoma (RCC) patients with imperative indications for nephron preservation, where PN is a high-risk procedure due to complexity (RENAL score 10-12). Axitinib 5 mg was administered twice daily for 8 weeks with repeat imaging at completion, followed by surgery. The primary outcome was successful completion of planned PN following axitinib treatment. Secondary objectives included changes in tumour diameter, RENAL nephrometry score, renal function and Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, and surgical complications. RESULTS: Twenty-seven patients were enrolled (median age 69 years). Prior to therapy, twenty patients (74.0%) had ≥ clinical T3a staged tumours. Axitinib resulted in reductions in tumour diameter (7.5 vs 6.2 cm; P < 0.001) and RENAL score (11 vs 10; P < 0.001). Nine patients (33.3%) had partial response based on RECIST and nine (33.3%) were clinically downstaged. PN was performed in twenty patients (74.0%); twenty-five patients (96.2%) had negative margins. Six patients (22.2%) had Clavien III-IV complications. The median change in estimated glomerular filtration rate (preoperative to last follow-up) was 8.5 mL/min/1.73 m2 . CONCLUSION: Neoadjuvant axitnib resulted in reductions in tumour size and complexity, enabling safe and feasible PN and functional preservation in patients with complex renal masses and imperative indication.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Hakimi K, Campbell SC, Nguyen MV, et al. PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy. BJU Int. 2024. PMID: 37916303. doi:10.1111/bju.16217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。